Finasteride. A review of its use in male pattern hair loss

Drugs

Volumn 57, Issue 1, 1999, Pages 111-126

  McClellan, Karen J ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; ANDROSTANOLONE; ANTIINFECTIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYTOCHROME P450 ISOENZYME; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FINASTERIDE; GLIBENCLAMIDE; MINOXIDIL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENAZONE; PROPRANOLOL; TESTOSTERONE; WARFARIN;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; EJACULATION; ERECTILE DYSFUNCTION; GENETIC PREDISPOSITION; HAIR GROWTH; HUMAN; HYPOSPADIAS; MALE; MALE SEXUAL DYSFUNCTION; MALE TYPE ALOPECIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PREGNANCY; REVIEW; SCALP HAIR; TESTOSTERONE METABOLISM; TOPICAL DRUG ADMINISTRATION;

ALOPECIA; ANIMALS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; HYDROXYTESTOSTERONES; MALE;

EID: 0032947121     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957010-00014     Document Type: Review

References (54)

1. 1. Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990 Apr; 70: 1136-41
2. 2. Stoner E. The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990 Nov 20; 37: 375-8
3. 3. Andersson S, Berman DM, Jenkins EP, et al. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991 Nov 14; 354: 159-61
4. 4. Jenkins EP, Andersson S, Imperato-McGinley J, et al. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992 Jan; 89: 293-300
5. 5. Chen W, Zouboulis CC, Orfanos CE. The 5α-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996; 193: 177-84
6. 6. Thiboutot D, Harris G, Iles V, et al. Activity of the type 1 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995; 105: 209-14
7. 7. Eicheler W, Dreher M, Hoffmann R, et al. Immunohistochemical evidence for differential distribution of 5α-reductase isoenzymes in human skin. Br J Dermatol 1995; 133: 371-6
8. 8. Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993 Aug; 92: 903-10
9. 9. Hoffmann R, Eicheler W, Happle R. Finasteride is the main inhibitor of 5α-reductase activity in dermal papillae of human hair follicles [abstract no. 342]. J Invest Dermatol 1998 Apr; 110 (4): 529
10. 10. Olsen EA. Androgenetic alopecia. In: Disorders of hair growth: diagnosis and treatment. New York: McGraw-Hill, Inc., 1993: 257-83
11. 11. Tian G. In vivo time-dependent inhibition of human steroid 5α-reductase by finasteride. J Pharm Sci 1996 Jan; 85: 106-11
12. 12. Mellin TN, Busch RD, Rasmusson GH. Azasteroids as inhibitors of testosterone 5α-reductase in mammalian skin. J Steroid Biochem Mol Biol 1993; 44: 121-31
13. 13. Nguyen QH, Chen T, Wang X, et al. Finasteride inhibits 5α-reductase activity in human dermal fibroblasts: prediction of its therapeutic application in androgen-related skin diseases. Int J Dermatol 1995 Oct; 34: 720-5
14. 14. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998; 39 (4 Pt 1): 578-89
15. 15. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994 Sep: 79: 703-6
16. 16. Waldstreicher J, Fiedler V, Hordinsky M, et al. Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness [abstract]. J Invest Dermatol 1994 Apr; 102: 615
17. 17. Uygur C, Arik I, Erol D. The effect of an 5-α reductase inhibitor - finasteride - on serum levels hypophyseal, adrenal and gonadal hormones and its clinical significance: a prospective study [abstract]. Br J Urol 1997 Sep; 80 Suppl. 2: 205
18. 18. Denti L, Pasolini G, Sanfelici L, et al. Androgens and lipid metabolism: effects of an inhibitor of 5alpha-reductase (finasteride) on HDL-cholesterol and Lp(a) [abstract]. 66th Congress of the European Atherosclerosis Society 1996 Jul 13-17: 168
19. 19. Jaffe A, Matzkin H, Gilad S, et al. Effect of 5-alpha-reductase inhibition on sex-hormone-binding globulin in elderly men. Horm Res 1994; 41 (5-6): 215-7
20. 20. Rittmaster RS, Antonian L, New MI, et al. Effect of finasteride on adrenal steroidogenesis in men. J Androl 1994 Jul-Aug; 15: 298-301
21. 21. Rittmaster RS, Lemay A, Zwicker H, et al. Effect of finasteride, a 5α-reductase inhibitor, on serum gonadotropins in normal men. J Clin Endocrinol Metab 1992 Aug; 75: 484-8
22. 22. Matzkin H, Chen J, Lewyshon O, et al. Effects of long term treatment with finasteride (MK-906), a 5-alpha-reductase inhibitor, on circulating LH, FSH, prolactin and estradiol. Horm Metab Res 1992 Oct; 24: 498-9
23. 23. Merck & Co. Propecia (finasteride) prescribing information. West Point (PA), 1997
24. 24. MRL clinical study report, multicenter study: a double-blind, randomized, placebo-controlled multicenter study to evaluate the safety of low-dose finasteride in male volunteers. Merck Research Laboratories 1996 (protocol 094) (Data on file)
25. 25. Diani AR, Mulholland MJ, Shull KL, et al. Hair growth effects of oral administration of finasteride, a steroid 5α-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 1992 Feb; 74: 345-50
26. 26. Peters DH, Sorkin EM. Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993 Jul; 46: 177-208
27. 27. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974 Dec 27; 186: 1213-5
28. 28. Guess HA, Heyse JF, Gormley GJ, et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American phase III clinical trial. Urol Clin North Am 1993 Nov; 20: 627-36
29. 29. Matzkin H, Chen JZ, Weisman Y, et al. Prolonged treatment with finasteride (a 5α-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol 1992 Nov; 37: 432-6
30. 30. Rhodes L, Harper J, Uno H, et al. The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides). J Clin Endocrinol Metab 1994 Oct; 79: 991-6
31. 31. Lasseter K. An open-label, multiple-dose study to investigate the pharmacokinetics of finasteride 1mg administered orally in healthy adult male subjects. MRL clinical study report; Merck Research Laboratories 1997; protocol 102 (Data on file)
32. 32. Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991; 16: 15-21
33. 14C]finasteride after oral administration in humans. Drug Metab Dispos 1992 Mar-Apr; 20: 148-55
34. 34. Winchell GA, Gregoire S, Constanzer ML, et al. Pharmacokinetics and oral bioavailability of the 5α-reductase inhibitor finasteride in man [abstract]. Pharm Res 1990 Sep; 7 Suppl.: S-251
35. 35. Propecia (finasteride) original NDA application clinical documentation. Merck Research Laboratories. D: clinical efficacy and safety; volume 1.23. (Data on file)
36. 36. Gregoire S, Winchell GA, Constanzer M, et al. Multiple dose pharmacokinetics of finasteride, a 5α-reductase inhibitor in men 45-60 and ≥70 years old [abstract]. Pharm Res 1990 Sep; 7 Suppl.: S-53
37. 37. Gregorie S, Winchell G, Constanzer M, et al. The effect of renal function on the disposition of finasteride, a new 5α-reductase inhibitor [abstract]. J Clin Pharmacol 1991 Sep: 31: 859
38. 38. Waldstreicher J, Thiboutot D, Dunlap F, et al. The effects of finasteride in men with frontal male pattern hair loss. Aust J Dermatol 1997; 38 (Suppl. 2): 101-2
39. 39. MRL clinical study report, multicenter study: a 6-month, double-blind, randomized, placebo-controlled, multicenter study followed by a 6-month, double-blind, randomized study extension to determine the effect of low doses of finasteride on hair loss in male patients with androgenetic alopecia (male pattern baldness). Merck Research Laboratories 1996 (protocols 081-00 and 081-10). (Data on file)
40. 40. Barber B, Kaufman KD, Kozloff R, et al. Development and validation of a men's hair growth questionnaire [abstract]. Drug Info J 1997; 31 (4): 1409-10
41. 41. MRL clinical study report, multicenter study: a double-blind, randomized, placebo-controlled, multicenter study to determine the effect of finasteride on hair loss in men with androgenetic alopecia (male pattern baldness). Merck Research Laboratories 1996 (protocol 087-03). (Data on file)
42. 42. MRL clinical study report, multicenter study: a double-blind, randomized, placebo-controlled, multicenter study to determine the effect of finasteride on hair loss in men with androgenetic alopecia (male pattern baldness). Merck Research Laboratories 1996 (protocol 089-03). (Data on file)
43. 43. MRL clinical study report, multicenter study: a double-blind,placebo-controlled multicenter study to determine the effect of finasteride in men with androgenetic alopecia and frontal baldness. Merck Research Laboratories 1996 (protocol 092). (Data on file)
44. 44. MRL clinical study report (synopsis), multicenter study: a double-blind, placebo-controlled study to investigate the effects of finasteride on DHT and testosterone in scalp skin and sebum. Merck Research Laboratories 1996 (protocol 065). (Data on file)
45. 45. Merck & Co. Inc. Worldwide Product Circular: Propecia (finasteride, MSD). USA, 1997
46. 46. Bergfeld WF. Androgenetic alopecia: an autosomal dominant disorder. Am J Med 1995 Jan 16; 98: 95S-8S
47. 47. Norwood O'TT. Male pattern baldness: classification and inci dence. South Med J 1975; 68 (11): 1359-65
48. 48. Sasson M, Shupack JL, Stiller MJ. Status of medical treatment for androgenetic alopecia. Int J Dermatol 1993 Oct; 32: 701-6
49. 49. Pharmacia & Upjohn. Regaine topical solution. UK Data Sheet
50. 50. Greenberg JH, Katz M. Treatment of androgenetic alopecia with a 7.5% herbal preparation. J Dermatol Treat 1996; 7: 159-62
51. 51. Piérard GE, Piérard-Franchimont C, Nikkels-Tassoudji N, et al. Improvement in the inflammatory aspect of androgenetic alopecia: a pilot study with an antimicrobial lotion. J Dermatol Treat 1996; 7: 153-7
52. 52. Maddin WS, Bell PW, James JHM. The biological effects of a pulsed electrostatic field with specific reference to hair: electronichogenesis. Int J Dermatol 1990 Jul-Aug; 29: 446-50
53. 53. Toshitani S, Nakayama J, Yahata T, et al. A new apparatus for hair regrowth in male-pattern baldness. J Dermatol 1990; 17: 240-6
54. 54. Roberts J, Hordinsky M, Olsen E, et al. The effect of finasteride in post-menopausal women with androgenetic alopecia [abstract no. 103]. Hair Workshop. Brussels, May 1998